Key points are not available for this paper at this time.
Should DTG + 3TC demonstrate high rates of virologic suppression, this regimen will be cost-effective and would save >500 million in ART costs in the United States over 5 years.
Girouard et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: